Viatris (VTRS) - 7.42% Below 52-Week High: Buy or Wait?

Stock Details

Viatris Inc (VTRS), a prominent company in the healthcare sector within the drug manufacturers - specialty & generic industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $16.73. Over the past 52 weeks, it has ranged between $8.41 and $18.07. This places the current price at 92.6% of its 52-week high and 98.9% above its 52-week low. Recent trading volume was recorded at 4,668,061. The International Securities Identification Number (ISIN) for this stock is US92556H2067.

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Forward P/E

7.12

PEG Ratio

1.12

Reasonably valued

Price to Book

1.40

EV/EBITDA

13.22

EPS (TTM)

-$0.30

Price to Sales

1.40

Beta

0.90

Less volatile than market

Q:How is VTRS valued relative to its earnings and growth?

Valuation data is not available for this stock.

Q:What is VTRS's risk profile compared to the market?

With a beta of 0.90, Viatris Inc is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 1.40 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

-2.04%

Operating Margin

6.78%

EBITDA

$4.13B

Return on Equity

-1.96%

Return on Assets

2.31%

Revenue Growth (YoY)

8.10%

Earnings Growth (YoY)

-70.60%

Q:How profitable and efficient is VTRS's business model?

Viatris Inc achieves a profit margin of -2.04%, meaning it retains $-2.04 from every $100 in revenue after all expenses. This relatively low margin suggests the company operates in a competitive environment or high-cost industry where profitability is challenging. The operating margin of 6.78% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at -1.96% and ROA at 2.31%, the company achieves moderate returns on invested capital.

Q:What are VTRS's recent growth trends?

Viatris Inc's revenue grew by 8.10% year-over-year, showing steady progress in growing the business. This positive trajectory indicates the company maintains competitive positioning in its markets. Earnings decreased by 70.60% year-over-year, reflecting the bottom-line impact of business performance. These growth metrics should be evaluated against DRUG MANUFACTURERS - SPECIALTY & GENERIC industry averages for proper context.

Dividend Information

Dividend Per Share

$0.48

Dividend Yield

2.70%

Ex-Dividend Date

May 22, 2026

Dividend Date

Jun 17, 2026

Q:What dividend income can investors expect from VTRS?

Viatris Inc offers a dividend yield of 2.70%, paying $0.48 per share annually. This above-average yield of 2-4% provides meaningful income while still allowing the company to reinvest for growth. It compares favorably to the S&P 500 average and offers competitive returns versus bonds in the current rate environment. To receive the next dividend, shares must be purchased before the ex-dividend date of May 22, 2026.

Q:How reliable is VTRS's dividend for long-term investors?

The dividend sustainability can be assessed through the payout ratio - Viatris Inc pays $0.48 per share in dividends against earnings of -$0.30 per share, resulting in a payout ratio of -160.00%. This conservative payout below 30% indicates excellent dividend safety with substantial room for future increases. The company retains most earnings for growth while still rewarding shareholders. The next dividend payment is scheduled for Jun 17, 2026.

Company Size & Market

Market Cap

$20.4B

Revenue (TTM)

$14.56B

Revenue/Share (TTM)

$12.54

Shares Outstanding

1.16B

Book Value/Share

$12.59

Asset Type

Common Stock

Q:What is VTRS's market capitalization and position?

Viatris Inc has a market capitalization of $20.4B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 1.16B shares outstanding, the company's ownership is widely distributed. As a participant in the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry, it competes with other firms in this sector.

Q:How does VTRS's price compare to its book value?

Viatris Inc's book value per share is $12.59, while the current stock price is $16.73, resulting in a price-to-book (P/B) ratio of 1.33. This reasonable premium to book value suggests the market values the company's earnings power and intangible assets appropriately. Most profitable companies trade between 1-3x book value. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$17.94

7.23% upside potential

Analyst Recommendations

Strong Buy

Buy

Hold

Sell

Strong Sell

Q:How reliable are analyst predictions for VTRS?

10 analysts cover VTRS with 50% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The mixed views reflect uncertainty about the outlook. The consensus target of $17.94 implies 7.2% upside, but targets are often adjusted to follow price moves rather than predict them.

Q:What is the Wall Street consensus on VTRS?

Current analyst recommendations:1 Strong Buy, 4 Buy, 4 Hold, 01 Strong Sell. The neutral stance suggests uncertainty or fair valuation at current levels.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Aug 2, 2026, 02:45 AM

Viatris Inc (VTRS) Stock